The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence

In the last few years it has been demonstrated that approximately 4% of non-small-cell lung cancer is driven by an ALK gene rearrangement. When such a rearrangement occurs an oncogene addicted state appears to then exist within the cancer cell. Crizotinib, an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, is effective in preclinical models of ALK-rearranged lung cancer, and has demonstrated high response rates in Phase I/II clinical trials in this sub-population. This review summarizes ALK biology, recent developments in techniques for the detection of ALK rearrangements, clinical characteristics of this population and relevant clinical trial results. Following filing for accelerated approval, crizotinib may soon be licensed for the treatment of ALK-positive non-small-cell lung cancer in the USA as well as worldwide.

[1]  A. Iafrate,et al.  A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[2]  P. Jänne,et al.  Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.

[3]  K. Jöckel,et al.  Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. , 2006, Lung cancer.

[4]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[5]  J. Maris,et al.  Inhibition of ALK Signaling for Cancer Therapy , 2009, Clinical Cancer Research.

[6]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[7]  R. Siebert,et al.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. , 2000, Blood.

[8]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[9]  M. Ladanyi,et al.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). , 2000, The American journal of pathology.

[10]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[11]  K. Pulford,et al.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). , 2000, Blood.

[12]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[13]  Ping Yang,et al.  Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. , 2009, Human pathology.

[14]  K. Garber.  ALK, lung cancer, and personalized therapy: portent of the future? , 2010, Journal of the National Cancer Institute.

[15]  S. Raimondi,et al.  Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum , 2011, Modern Pathology.

[16]  W. Franklin,et al.  Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  A. Iafrate,et al.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Takashi Yamasaki,et al.  Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma , 2010, Journal of Clinical Pathology.

[19]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[20]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[21]  D. Gandara,et al.  A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue. , 2010 .

[22]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[23]  E. Campo,et al.  A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. , 2000, Cancer research.

[24]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[25]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[26]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[27]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[28]  F. Hirsch,et al.  Finding ALK-positive lung cancer: what are we really looking for? , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[30]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[31]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  W. Franklin,et al.  Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.

[33]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[34]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[35]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[36]  H. Mano.  Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer , 2008, Cancer science.

[37]  F. Cappuzzo,et al.  ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). , 2010 .

[38]  R. A. Robinson,et al.  Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.

[39]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[40]  A. Gemma,et al.  F1000 highlights , 2010 .

[41]  R. Palmer,et al.  Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.

[42]  Ming Zhou,et al.  Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[43]  D. Camidge,et al.  A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). , 2010 .

[44]  A. Iafrate,et al.  Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Hyojin Kim,et al.  Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  C. Griffin,et al.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.

[47]  D. Schrump,et al.  Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor , 2003, Laboratory Investigation.

[48]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[49]  H. Sugimura,et al.  EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.

[50]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Ping Yang,et al.  Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.